Nv-5138

Nv-5138

SCHEMBL18762500

CC(C)(CC(N)C(=O)O)C(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.41
GRIK1 P39086 5/20 0.40
PTGS1 P23219 2/20 0.39
SLC7A11 Q9UPY5 1/20 0.39
SLC1A2 P43004 6/20 0.38
SLC1A3 P43003 5/20 0.38
SLC1A1 P43005 5/20 0.38
NOS2 P35228 3/20 0.37
NOS3 P29474 2/20 0.37
NOS1 P29475 2/20 0.37
GRIK2 Q13002 3/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GSR P00390 1/20 0.37
CYP1A2 P05177 1/20 0.37
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nv-5138 SCHEMBL18774929 1.00 SLC7A5 (0.41) SLC7A5GRIK1PTGS1SLC7A11SLC1A2
Nv-5138 SCHEMBL18762589 1.00 SLC7A5 (0.41) SLC7A5GRIK1PTGS1SLC7A11SLC1A2
SCHEMBL18762570 0.83 ODC1 (0.31) NOS2NOS3NOS1
SCHEMBL25633982 0.83 NOS2 (0.30) NOS2NOS3NOS1
SCHEMBL18762569 0.83 ODC1 (0.31) NOS2NOS3NOS1
SCHEMBL18774931 0.83 ODC1 (0.31) NOS2NOS3NOS1
SCHEMBL18775026 0.82 SLC7A5 (0.50) SLC7A5GRIK1PTGS1SLC7A11SLC1A2
SCHEMBL18775031 0.82 SLC7A5 (0.50) SLC7A5GRIK1PTGS1SLC7A11SLC1A2
SCHEMBL6345113 0.82 SLC7A5 (0.50) SLC7A5GRIK1PTGS1SLC7A11SLC1A2
Hydrochloric Acid SCHEMBL6356435 0.80 SLC7A5 (0.48) SLC7A5GRIK1PTGS1SLC7A11SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARM INC (US) 2026-02-05 US disclosed
US-12465583-B2 Methods of treatment using an mTORC1 modulator NAVITOR PHARMACEUTICALS, INC. (US) 2025-11-11 US disclosed
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-12378263-B2 Modulators of sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-08-05 US disclosed
US-20250188017-A1 POLYMORPHIC COMPOUNDS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2025-06-12 US disclosed
EP-3615019-B1 MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION NAVITOR PHARM INC (US) 2025-06-04 EP disclosed
EP-4556069-A2 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2025-05-21 EP disclosed
US-12252456-B2 Polymorphic compounds and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2025-03-18 US disclosed
WO-2024097285-A1 MODULATORS OF mTORC1 ACTIVITY AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2024-05-10 WO disclosed
US-20240091184-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2024-03-21 US disclosed
US-20190048029-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2019-02-14 US disclosed
US-20180333381-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2018-11-22 US disclosed
WO-2018200625-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-11-01 WO disclosed
US-10100066-B2 Modulators of sestrin-GATOR2 interaction and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-16 US disclosed
EP-3364958-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2018-08-29 EP disclosed
US-20170114080-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2017-04-27 US disclosed
WO-2017070518-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2017-04-27 WO disclosed
WO-2017070518-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2017-04-27 WO disclosed
US-20170114080-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2017-04-27 US disclosed
US-20170114080-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2017-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034084-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF RICTOR, RPTOR, MTOR SLC7A5 374/4885GRIK1 940/4885PTGS1 3842/4885
US-20240091184-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF GATD3, GABRR2, GABRR3 SLC7A5 2349/4885GRIK1 160/4885PTGS1 4308/4885
US-12465583-B2 Methods of treatment using an mTORC1 modulator RPTOR, MTOR, RICTOR SLC7A5 1713/4885GRIK1 1959/4885PTGS1 3465/4885
US-20170114080-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF GATD3, GABRR2, GABRR3 SLC7A5 2349/4885GRIK1 160/4885PTGS1 4308/4885
US-10100066-B2 Modulators of sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 SLC7A5 2349/4885GRIK1 160/4885PTGS1 4308/4885
US-12378263-B2 Modulators of sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 SLC7A5 2349/4885GRIK1 160/4885PTGS1 4308/4885
US-20250188017-A1 POLYMORPHIC COMPOUNDS AND USES THEREOF MTOR, RICTOR, RPTOR SLC7A5 1287/4885GRIK1 2763/4885PTGS1 2878/4885
US-12252456-B2 Polymorphic compounds and uses thereof MTOR, RICTOR, RPTOR SLC7A5 1287/4885GRIK1 2763/4885PTGS1 2878/4885
US-20190048029-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF GATD3, GABRR2, GABRR3 SLC7A5 2349/4885GRIK1 160/4885PTGS1 4308/4885
US-12427130-B2 Modulators of Sestrin-GATOR2 interaction and uses thereof GATD3, GABRR2, GABRR3 SLC7A5 2349/4885GRIK1 160/4885PTGS1 4308/4885
US-20180333381-A1 MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF GATD3, GABRR2, GABRR3 SLC7A5 2349/4885GRIK1 160/4885PTGS1 4308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.